Dasatinib
Back to searchMolecule Structure
Scientific Name
Dasatinib
Description of the Drug
Dasatinib is a tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01254
http://www.drugbank.ca/drugs/DB01254
Brand Name(s)
Dasatinib, Sprycel
Company Owner(s)
Apotex Inc, Bristol Myers Squibb Co
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Tyrosine-protein kinase ABL | SINGLE PROTEIN | INHIBITOR | CHEMBL1862 |
Bcr/Abl fusion protein | CHIMERIC PROTEIN | INHIBITOR | CHEMBL2096618 |
Stem cell growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL1936 |
Ephrin type-A receptor 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL2068 |
SRC | PROTEIN FAMILY | INHIBITOR | CHEMBL2363074 |
Platelet-derived growth factor receptor beta | SINGLE PROTEIN | INHIBITOR | CHEMBL1913 |
Clinical Trial(s)
Unichem Links
Atlas | Dasatinib | ||
SureChEMBL | SCHEMBL8226 | ||
PharmGKB | PA162372878 | ||
Human Metabolome Database | HMDB0015384 | ||
DrugBank | DB01254 | ||
PubChem: Thomson Pharma | 14859389 | ||
PubChem | 3062316 | ||
LINCS | LSM-1020 | ||
Nikkaji | J2.086.852J | ||
PDBe | 1N1 | ||
BindingDB | 13216 | ||
EPA CompTox Dashboard | DTXSID4040979 | ||
DrugCentral | 785 | ||
Brenda | 5015 | ||
ChemicalBook | CB4506696 | CB81565483 | |
Guide to Pharmacology | 5678 | ||
rxnorm | DASATINIB ANHYDROUS | SPRYCEL | DASATINIB |
PubChem: Drugs of the Future | 12015788 | ||
ChEBI | 49375 | ||
ZINC | ZINC000003986735 |